Comparison Between Intravitreal Bevacizumab and Triamcinolone for Macular Edema Secondary to Branch Retinal Vein Occlusion

Published on Dec 4, 2009in Korean Journal of Ophthalmology
· DOI :10.3341/KJO.2009.23.4.259
Jin Young Kim10
Estimated H-index: 10
(Sacred Heart Hospital),
Sung Pyo Park10
Estimated H-index: 10
(Hallym University)
Sources
Abstract
Purpose To compare the effects of intravitreal bevacizumab to those of triamcinolone acetonide injection for the treatment of macular edema secondary to branch retinal vein occlusion.
📖 Papers frequently viewed together
881 Citations
555 Citations
219 Citations
References30
Newest
Purpose of reviewNew treatment modalities for branch retinal vein occlusion have recently been introduced. The role of intravitreal bevacizumab injections will be discussed and compared with laser photocoagulation and other novel intravitreal pharmacotherapies.Recent findingsArgon laser photocoagula
47 CitationsSource
Purpose:To evaluate the efficacy of primary and secondary (following grid laser photocoagulation) intravitreal triamcinolone acetonide (IVTA) injection for the treatment of macular edema associated with branch retinal vein occlusion (BRVO).Methods:Eyes with macular edema secondary to BRVO and best-c
39 CitationsSource
Purpose: To report the 6-month anatomical and visual outcomes after injecting two different doses of intravitreal bevacizumab in patients with macular edema secondary to branch retinal vein occlusion (BRVO). Methods: An interventional, retrospective multicenter study of 45 eyes that were treated with at least one intravitreal injection (24 eyes, 1.25 mg; 21 eyes, 2.5 mg) of bevacizumab is reported. The main outcome measures were the central 1-mm macular thickness (CMT) and the change in ETDRS li...
81 CitationsSource
Purpose: To report the authors' experience after intravitreal bevacizumab (Avastin, Genentech) injection in patients with macular edema (ME) secondary to branch retinal vein occlusive disease (BRVO). Methods: A consecutive retrospective review of patients with ME secondary to BRVO who were treated with intravitreal bevacizumab (1.25 mg/0.05 mL). Patients underwent complete ophthalmic evaluation, which included nonstandardized Snellen visual acuity testing, optical coherence tomography (OCT), and...
219 CitationsSource
Purpose: To investigate the improvement of visual acuity with the different effects of ischemic and perfusion type branched retinal vein occlusion (BRVO), and explore the relationship between defects of the macular capillary network and intravitreal injection of triamcinolone acetonide (IVTA) for treatment of BRVO secondary to macular edema. Methods: We compared macular capillary network condition, improvement of visual acuity due to ischemic range, and decrease of macular edema between 23 perfu...
4 Citations
#1Kai-Chun Cheng (KMU: Kaohsiung Medical University)H-Index: 1
#2Wen-Chuan Wu (KMU: Kaohsiung Medical University)H-Index: 6
We designed a case series study to evaluate the outcome of intravitreal triamcinolone acetonide for the treatment of macular edema due to branch retinal vein occlusion (BRVO). The prospective comparative nonrandomized clinical interventional study included 27 patients (27 eyes) with macular edema due to BRVO. The study group consisted of 16 patients who had accepted an intravitreal injection (IVI) of 4 mg triamcinolone acetonide. The control group included 11 patients without IVI of triamcinolon...
16 CitationsSource
#1Gesine B. JaissleH-Index: 22
#2Focke ZiemssenH-Index: 32
Last. K. U. Bartz-SchmidtH-Index: 19
view all 9 authors...
Mit der Entwicklung von VEGF-Inhibitoren zur Therapie des Makulaodems nach venosen retinalen Verschlussen besteht die Moglichkeit, direkt in die pathogenetische Kaskade einzugreifen. Erste Studienergebnisse mit der intravitrealen Injektion des VEGF-Antikorpers Bevacizumab sind viel versprechend und weisen auf das Potenzial einer neuen hoch wirksamen antiodematosen Therapie bei retinalen Gefasverschlussen hin. In vielen Fallen kann innerhalb von Tagen ein deutlicher Ruckgang des Makulaodems errei...
74 CitationsSource
#1Diana Iturralde (Manhattan Eye, Ear and Throat Hospital)H-Index: 5
#2Richard F. Spaide (Manhattan Eye, Ear and Throat Hospital)H-Index: 108
Last. J.M. Klancnik (Manhattan Eye, Ear and Throat Hospital)H-Index: 6
view all 8 authors...
132 Citations
Purpose: To report the short term anatomic and visual acuity response after intravitreal injection of bevacizumab (Avastin, Genentech) in patients with macular edema due to central retinal vein occlusion (CRVO). Methods: The authors conducted a retrospective study of patients with macular edema due to CRVO who were treated with at least one intravitreal injection of bevacizumab 1.25 mg in 0.05 mL. Patients underwent Snellen visual acuity testing, optical coherence tomography (OCT) imaging, and o...
440 CitationsSource
#1Osman Çekiç (Columbia University)H-Index: 26
#2Stanley ChangH-Index: 55
Last. OberH-Index: 1
view all 8 authors...
Purpose: To evaluate the efficacy of intravitreal triamcinolone injection in eyes with macular edema due to branch retinal vein occlusion (BRVO) over a 2-year period. Methods: The authors performed a retrospective chart review of 13 eyes of 13 patients (mean age 68 years) who underwent intravitreal injections with 4 mg triamcinolone acetonide for macular edema due to BRVO. Six eyes received a single injection. Repeated injections were performed in one eye twice, four eyes three times, and two ey...
131 CitationsSource
Cited By30
Newest
#1Victor. A. de Vries (EUR: Erasmus University Rotterdam)H-Index: 1
#2Fabiana L. Bassil (EUR: Erasmus University Rotterdam)H-Index: 1
Last. Wishal D. Ramdas (EUR: Erasmus University Rotterdam)H-Index: 25
view all 3 authors...
The number of eye diseases treated with intravitreal injections is increasing. Obviously, an injection of fluid into the eye results in an increase of intraocular pressure (IOP), the main risk factor for glaucoma. However, the effect of these repeated IOP increases on the eye is unclear. Therefore, we performed a systematic review with meta-analyses. PubMed, Embase and Clinical Trials Registries were searched for articles investigating the relationship between intravitreal injections (anti-vascu...
7 CitationsSource
#1Juan Lyn Ang (Royal Free London NHS Foundation Trust)H-Index: 1
#2Sarah Ah-Moye (Royal Free London NHS Foundation Trust)H-Index: 1
Last. Hemal Mehta (USYD: University of Sydney)H-Index: 12
view all 8 authors...
This review assessed the real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion (BRVO). A meta-analysis of 2530 eyes from 48 real-world studies of therapies for macular oedema secondary to BRVO was conducted. Baseline characteristics, visual, anatomical and safety outcomes were recorded. The weighted mean and weighted estimates from random-effects models were calculated for visual acuity (VA) and central subfield thickness (CST) changes at 6, 12 and 24...
7 CitationsSource
#1Meng-Ju TsaiH-Index: 3
#2Yi-Ting HsiehH-Index: 15
Last. Yi-Jie PengH-Index: 3
view all 3 authors...
To compare the efficacy and safety between posterior sub-tenon injection of triamcinolone acetonide (PSTA) and intravitreal injection of bevacizumab (Avastin) (IVIA) in the treatment of macular edema secondary to retinal vein occlusion.A total of 45 eyes were retrospectively enrolled (23 eyes with intravitreal bevacizumab and 22 eyes with posterior sub-tenon triamcinolone acetonide). Main endpoints included logMAR of best-corrected visual acuity (BCVA), central macular thickness (CMT), and intra...
4 CitationsSource
#1Young Hee Yoon (UOU: University of Ulsan)H-Index: 30
#2Jong Woo Kim (Konyang University)H-Index: 16
Last. Susan SimonyiH-Index: 1
view all 10 authors...
Purpose: To evaluate the effect of dexamethasone intravitreal implant for macular edema (ME) following branch retinal vein occlusion (BRVO) in Korean patients. Methods: We performed a prospective, open-label, multicenter study of 71 patients with ME for < 3 months. Retreatment was allowed ≥4 months from the last injection. Results: At 6 and 12 months, mean ± SD best-corrected visual acuity (BCVA) improvement was 18.6 ± 12.9 and 15.3 ± 15.0 letters, respectively. Approximately 70% of maximum trea...
16 CitationsSource
#1Su Jin Yoo (Konyang University)H-Index: 4
#2Jae Hui Kim (Konyang University)H-Index: 13
Last. Jung Il Han (Konyang University)H-Index: 9
view all 6 authors...
PURPOSE: To evaluate the 3-month natural course of recurrent macular edema secondary to branch retinal vein occlusion (BRVO) treated with intravitreal bevacizumab. METHODS: This retrospective, observational study included 36 eyes with macular edema secondary to BRVO. All patients were initially treated with intravitreal bevacizumab for macular edema. Recurrence of macular edema was either not treated (untreated group) or treated with a single intravitreal bevacizumab injection (treated group). C...
2 CitationsSource
#1Jawahar Lal Goyal (MAMC: Maulana Azad Medical College)H-Index: 7
#2Richa Agarwal (MAMC: Maulana Azad Medical College)H-Index: 2
Last. Basudeb Ghosh (MAMC: Maulana Azad Medical College)H-Index: 10
view all 5 authors...
Purpose To evaluate pattern electroretinogram (pattern ERG) and anatomical changes in optical coherence tomography (OCT) in acute retinal vein occlusion with macular oedema after intravitreal triamcinolone acetonide (IVTA) injection.
Source
#1Yan Sun (WMU: Weifang Medical University)H-Index: 1
#2Yi Qu (SDU: Shandong University)H-Index: 1
AIM To compare the effects of intravitreal injection of bevacizumab (IVB) with intravitreal triamcinolone acetonide (IVTA) on the treatment of cystoid macular edema (CME) secondary to retinal vein occlusion (RVO).
6 CitationsSource
Retinal vein occlusions are important causes of loss of vision; indeed, they are the second most common retinal vascular disease, following diabetic retinopathy. For this reason alone, primary eye-care providers must be well versed in diagnosis and management. Risk factors, though not universally agreed upon, include but are not limited to advancing age, systemic hypertension, arteriolarsclerosis, diabetes, hyperlipidaemia, blood hyperviscosity, thrombophilia, ocular hypertension and glaucoma. T...
24 CitationsSource
#1Edith Poku (University of Sheffield)H-Index: 12
#2John Rathbone (Bond University)H-Index: 25
Last. Allan Wailoo (University of Sheffield)H-Index: 36
view all 7 authors...
Objectives To assess the safety of intravitreal bevacizumab (IVB) as a monotherapy and to evaluate the relationship between quality of treatment and adverse events. Data sources Cochrane Library, Ovid MEDLINE, MEDLINE in-process, Ovid EMBASE and Toxicology Literature Online (TOXLINE) from January 2009 to May 2012. Studies included in an earlier systematic review were also assessed for inclusion. Study eligibility criteria, participants and interventions Randomised controlled trials (RCTs), contr...
24 CitationsSource